Consider buying Novo Nordisk (NVO), as the stock appears "over punished" and offers a compelling value opportunity in the massive GLP-1 market. For growth investors, the upcoming Figma IPO is being called the "IPO of the year" due to its exceptional financial strength and market leadership. Microsoft (MSFT) and Meta (META) remain core holdings, as their aggressive AI investments are being heavily rewarded by the market. This trend is amplified by tariff uncertainty, which pushes capital towards these tech giants as relative safe havens. Investors should consider avoiding tariff-sensitive US industrials like Ford (F) and General Motors (GM) for now.

Microsoft (MSFT)

• The company reported a blockbuster quarter with total revenue surging 18% year-over-year to $76 billion.
• Microsoft is doubling down on Artificial Intelligence (AI), with capital spending (CapEx) climbing 27%. The company is planning to spend $30 billion on capital in the next quarter alone.
• The hosts noted that Microsoft may have invested more capital in the future than any organization in history, with the exception of countries during wartime. This massive spending is seen as paying off.
• Its cloud-based unit, Azure, grew an impressive 39%. The hosts mentioned that if Azure were valued on its own, it would be a trillion-dollar business.
• The stock was up 8% in pre-market trading following the earnings announcement. Along with Meta, it added a combined $550 billion in market capitalization overnight.
• The discussion highlighted that due to tariff uncertainty affecting other sectors, investors may be pushed towards tech giants like Microsoft, viewing them as a safer investment.

Takeaways

• The sentiment around Microsoft is overwhelmingly bullish. The company's massive investments in AI are being rewarded by the market and are driving significant growth, particularly in its Azure cloud division.
• Investors may see MSFT as a core holding for exposure to the AI boom, as it is establishing itself as a dominant leader in the space through immense capital expenditure.
• The company is also seen as a beneficiary of macroeconomic uncertainty (like tariffs), which could drive more capital into a smaller number of large-cap tech stocks.

Meta Platforms (META)

• Meta reported a huge Q2, with revenue of $47 billion (up 22%) and profit of $18 billion (up 36%).
• The company's user base grew by 6%, which is significant given its massive scale. The hosts noted this is equivalent to adding the entire population of Brazil to its platform in a year.
• Like Microsoft, Meta is on an AI hiring spree and investing heavily in capital expenditures ($17 billion in the quarter, double from last year). The market is said to "love" this aggressive spending on AI.
• The hosts noted that Meta's traditional advertising business is performing exceptionally well, likely enhanced by AI-powered targeting.
• CEO Mark Zuckerberg's vision for "personal super intelligence" was discussed, but the core investment thesis remains tied to the company's massive spending and dominance in its field.

Takeaways

• The sentiment for Meta is very bullish. Its core advertising business is strong, user growth continues, and the market is rewarding its aggressive pivot and investment into AI.
• Despite the high spending, the company's profitability is surging, indicating strong operational efficiency.
• For investors, META represents another key player in the AI arms race that is currently being favored by the market, making it a potential "safe haven" amid broader economic uncertainty.

Novo Nordisk (NVO)

• The company's shares were described as plummeting, dropping 30% at one point and wiping out $93 billion in market value.
• This was due to the company slashing its full-year guidance, citing weaker-than-expected U.S. growth for its popular weight-loss drugs Ozempic and Wegovy.
• The downturn is being blamed on increased competition from Eli Lilly and, more significantly, cheaper compounded GLP-1 knockoffs.
• Despite the company's struggles, host Scott Galloway remains extremely bullish on the underlying GLP-1 drug category, calling it more important for society than AI.
• Galloway stated that the stock has been "over punished" and is now a "great value." He noted its Price-to-Earnings (P/E) ratio has fallen to 14.6, compared to its five-year average of 33 and the S&P 500 average of 26.

Takeaways

• The podcast presents a contrarian, bullish opportunity for Novo Nordisk. While the company faces significant competitive headwinds, the stock may have been sold off too aggressively.
• Host Scott Galloway explicitly stated, "I actually think the stock is a buy right now," viewing it as a chance to invest in a market leader in a massive growth category at a discounted valuation.
• Investors should be aware of the risks, including intense competition from both branded drugs (like Eli Lilly's) and cheaper generic alternatives, which are impacting Novo Nordisk's market share and pricing power.

Figma (IPO)

• Host Scott Galloway named Figma his "IPO of the year." Figma is a collaborative design software company.
• The company was supposed to be acquired by Adobe for $20 billion, but the deal was blocked by EU regulators. This is seen as a major positive, fostering more competition and providing a great opportunity for public investors.
• Figma is described as having exceptionally strong financials. It has a "Rule of 40" score of 64 (44% growth + 20% profit margin), placing it in the top tier of software-as-a-service (SaaS) companies.
• The IPO was reportedly 40 times oversubscribed, indicating massive institutional demand for the shares.
• Galloway believes design is a booming field and that Figma is the leading, modern tool, comparing it to Toyota (easy to use, efficient) versus Adobe's Mercedes (powerful but over-engineered).

Takeaways

• The sentiment for the Figma IPO is extremely bullish. It is presented as a rare opportunity to invest in a high-growth, profitable, and fundamentally sound company that is a leader in its category.
• The massive oversubscription suggests the stock could see a significant price increase on its first day of trading. Galloway predicts it will "close up monstrously."
• This is an opportunity to invest in a "pure play" design software leader, a market that is seen as having long-term growth potential and being somewhat immune to disruption from AI.

Investment Theme: Tariffs & US Industrials

• The discussion around tariffs was overwhelmingly negative, framing them as a tax on American consumers and a policy that makes U.S. companies less competitive.
• Companies like Ford (F) and General Motors (GM) were mentioned as being negatively impacted by the chaos and uncertainty of the trade policy. It was noted that Ford is losing money for the first time since 2023.
• A key insight was that tariff policies are creating a major distortion in the market. They are kneecapping industrial and manufacturing companies while inadvertently pushing investment capital towards tech and AI companies, which are largely unaffected.

Takeaways

• Investors should consider the significant risk that tariffs and trade uncertainty pose to companies in the manufacturing, industrial, and consumer goods sectors.
• This political risk creates an uneven playing field, potentially making non-tech stocks less attractive until there is more clarity.
• The discussion suggests a portfolio strategy of being underweight in sectors vulnerable to tariffs and overweight in sectors that are immune, such as large-cap U.S. tech.

Investment Theme: GLP-1 Weight-Loss Drugs

• This category, which includes drugs like Ozempic, Wegovy, and Mounjaro, was described as one of the most important technological developments of the last decade, with the potential for massive societal and economic impact.
• The market is experiencing intense competition, not just between major players like Novo Nordisk and Eli Lilly, but also from cheaper "knockoff" compounded versions, as seen with the success of companies like Hims & Hers (HIMS).
• The long-term growth potential is considered enormous, with only 8% of Americans having tried a GLP-1 drug, while about a third are interested.

Takeaways

• The GLP-1 drug market is a high-growth, high-stakes sector. While the potential is huge, investors must be prepared for volatility and intense competition.
• The discussion highlights two ways to play this theme:
  • Value/Contrarian: Investing in a beaten-down leader like Novo Nordisk (NVO).
  • Momentum: Investing in a competitor that is gaining market share, such as Eli Lilly (LLY).
• The rise of cheaper alternatives indicates that pricing pressure will be a key factor for all companies in this space moving forward.